The competitiveness of the biomedical industry in Suzhou Industrial Park ranks first in China, with an output value of 80 billion yuan last year

Intersection news on November 4, the biotechnology development center of the Ministry of science and technology of the people's Republic of China issued the report on the competitiveness evaluation and analysis of China's biomedical industrial park in 2019, and Suzhou Industrial Park ranked among the top in terms of various main indicators In the comprehensive ranking, Suzhou Industrial Park ranks the third, ranking first with ZhongGuanCun national independent innovation demonstration zone and Shanghai Zhangjiang High Tech Park Among them, Suzhou Industrial Park ranks first in the single ranking of industrial competitiveness with the highest gold content In the report, 107 national high-tech zones, 78 national economic development zones and 4 other parks were comprehensively and systematically investigated, and the data of each industrial park in the past three years were comprehensively compared, including 198 data of 34 themes, including industrial status, achievement transfer and transformation, R & D input and technical output, talents, enterprises, products, environment, etc., which are authoritative and instructive At present, in the field of biomedicine, Suzhou Industrial Park has gathered more than 20 top scientific research institutes and innovation institutions, including lengquangang laboratory, more than 1300 new drug enterprises represented by Cinda biology, cornerstone pharmaceutical, Yasheng pharmaceutical, etc., as well as major innovation teams led by dozens of Chinese and foreign academicians and more than 30000 high-end professional and technical talents Last year, Suzhou Industrial Park added 34 new clinical approvals for a new class of new drugs, accounting for about 20% of the country Last year, the output value of biomedical industry reached 80 billion yuan, an increase of nearly 30% year on year According to the plan, Suzhou Industrial Park will lay out a number of major scientific facilities, build a number of major innovation platforms, further attract top talents and projects in the world in the key areas of biomedical technology in the future, and strive to build into a biomedical industrial park with international first-class level.